Amyris (AMRS) Set to Announce Quarterly Earnings on Tuesday

Amyris (NASDAQ:AMRSGet Rating) will be posting its quarterly earnings results before the market opens on Tuesday, May 10th. Analysts expect Amyris to post earnings of ($0.24) per share for the quarter.

Amyris (NASDAQ:AMRSGet Rating) last issued its quarterly earnings data on Tuesday, March 1st. The biotechnology company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.23). The business had revenue of $64.80 million during the quarter, compared to the consensus estimate of $54.63 million. The company’s revenue for the quarter was down 18.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.44) earnings per share. On average, analysts expect Amyris to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of AMRS stock traded down $0.07 during trading hours on Wednesday, hitting $3.62. 7,807 shares of the company’s stock were exchanged, compared to its average volume of 3,970,470. Amyris has a fifty-two week low of $3.22 and a fifty-two week high of $17.42. The firm has a market cap of $1.15 billion, a P/E ratio of -1.90 and a beta of 1.63. The company has a quick ratio of 2.09, a current ratio of 2.37 and a debt-to-equity ratio of 1.26. The firm has a 50 day moving average of $4.32 and a two-hundred day moving average of $5.96.

A number of equities analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Amyris from a “strong sell” rating to a “hold” rating in a research report on Tuesday. initiated coverage on Amyris in a report on Thursday, March 31st. They issued a “sell” rating on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from, the stock has a consensus rating of “Buy” and a consensus price target of $19.17.

Several hedge funds have recently bought and sold shares of the company. Legal & General Group Plc grew its position in Amyris by 1.7% in the fourth quarter. Legal & General Group Plc now owns 137,498 shares of the biotechnology company’s stock worth $744,000 after acquiring an additional 2,305 shares during the period. LPL Financial LLC increased its stake in Amyris by 11.4% during the fourth quarter. LPL Financial LLC now owns 30,021 shares of the biotechnology company’s stock worth $162,000 after purchasing an additional 3,075 shares during the period. California State Teachers Retirement System boosted its stake in shares of Amyris by 5.3% in the fourth quarter. California State Teachers Retirement System now owns 235,363 shares of the biotechnology company’s stock valued at $1,273,000 after purchasing an additional 11,858 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Amyris in the third quarter valued at approximately $216,000. Finally, Vident Investment Advisory LLC increased its stake in Amyris by 6.7% during the 4th quarter. Vident Investment Advisory LLC now owns 372,081 shares of the biotechnology company’s stock worth $2,013,000 after buying an additional 23,228 shares during the period. Institutional investors and hedge funds own 49.43% of the company’s stock.

About Amyris (Get Rating)

Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets.

Read More

Earnings History for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with's FREE daily email newsletter.